- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05296447
Långtidsuppföljningsstudie av RGX-314 administrerad i det suprakoroidala utrymmet för deltagare med diabetisk retinopati
En långtidsuppföljningsstudie för att utvärdera säkerheten och effektiviteten av suprakoroidal administrering av RGX-314 för diabetesretinopati utan centruminvolverat diabetiskt makulaödem
This is a prospective study designed to evaluate the long-term safety and efficacy of ABBV-RGX-314. Eligible participants are those who were previously enrolled in a clinical study of DR with and without center involved-diabetic macular edema (CI-DME) in which they received suprachoroidal space (SCS) administration of ABBV-RGX-314. Enrollment of each participant in the current study should occur after the participant has completed either the end of study or early discontinuation visit in the previous (parent) clinical study. Participants will be followed for a total of 5 years post-ABBV-RGX-314 administration (inclusive of the parent study). As such, the total study duration for each participant may vary depending on when they enroll in the current study following ABBV-RGX-314 administration in the parent study.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
Arizona
-
Phoenix, Arizona, Förenta staterna, 85014
- Retinal Research Institute, LLC
-
-
California
-
Bakersfield, California, Förenta staterna, 93309
- California Retina Consultants
-
Beverly Hills, California, Förenta staterna, 90211
- Retina-Vitreous Associates Medical Group
-
Los Angeles, California, Förenta staterna, 90017
- Retinal Diagnostic Center
-
Mountain View, California, Förenta staterna, 94040
- Northern California Retina Vitreous Associates Medical Group Inc
-
Pasadena, California, Förenta staterna, 91107
- California Eye Specialists Medical Group, Inc
-
Poway, California, Förenta staterna, 92064
- Retina Consultants San Diego
-
Santa Barbara, California, Förenta staterna, 93103
- California Retina Consultants CRC
-
-
Georgia
-
Augusta, Georgia, Förenta staterna, 30909
- Southeast Retina Center, PC
-
-
Illinois
-
Oak Forest, Illinois, Förenta staterna, 60452
- University Retina and Macula Associates, PC
-
-
Maryland
-
Hagerstown, Maryland, Förenta staterna, 21740
- Cumberland Valley Retina Consultants
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02114
- Ophthalmic Consultants of Boston
-
-
Nevada
-
Reno, Nevada, Förenta staterna, 89502
- Sierra eye Associates
-
-
New Jersey
-
Teaneck, New Jersey, Förenta staterna, 07666
- New Jersey Retina
-
-
New Mexico
-
Albuquerque, New Mexico, Förenta staterna, 87109
- Vision Research Center Eye Associates of New Mexico
-
-
North Carolina
-
Durham, North Carolina, Förenta staterna, 27705
- Duke University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19107
- Mid Atlantic Retina
-
-
Tennessee
-
Germantown, Tennessee, Förenta staterna, 38138
- Charles Retina Institute, P.C
-
-
Texas
-
Austin, Texas, Förenta staterna, 78750
- Austin Clinical Research
-
The Woodlands, Texas, Förenta staterna, 77384
- Retina Consultants of Texas
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Must provide written, signed informed consent for this study
- Must have been enrolled in a previous clinical study of ABBV-RGX-314 for the treatment of DR with or without CI-DME and must have received an SCS injection of ABBV-RGX-314 in that study
- Must be willing and able to comply with all study procedures
Exclusion Criteria:
- None
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Övrig: Standard of Care
Dose Level (DL) 1-3 participants who received ABBV-RGX-314 in a parent study will continue to receive standard of care for the study duration. |
Standard of Care |
|
Övrig: Supplemental Treatment
DL4 participants from parent study will be eligible to receive supplement aflibercept through a prespecified timepoint based on protocol-specified criteria if they develop worsening CI-DME or high-risk proliferative diabetic retinopathy (PDR) in the study eye. |
Standard of Care Injection
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Incidence of ocular adverse events (AEs) and any serious adverse events (SAEs)
Tidsram: 5 years inclusive of the parent study
|
To evaluate the long-term safety of ABBV-RGX-314 |
5 years inclusive of the parent study
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Andel deltagare som behöver ytterligare ingrepp för okulära diabetiska komplikationer (t.ex. anti-VEGF intravitreal injektion eller PRP)
Tidsram: 5 år, inklusive föräldrastudien
|
5 år, inklusive föräldrastudien
|
|
Andel deltagare med eventuella synhotande okulära diabetiska komplikationer
Tidsram: 5 år, inklusive föräldrastudien
|
5 år, inklusive föräldrastudien
|
|
Incidences of non-ocular AEs and any Adverse Events of Special Interest
Tidsram: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in DR by ETDRS-DRSS on digital stereoscopic fundus photography
Tidsram: 5 years, inclusive of the parent study
|
5 years, inclusive of the parent study
|
|
Proportion of participants achieving 0-step (no change), a ≥1-step, a ≥2-step, or a ≥3-step or greater change in DR per ETDRS-DRSS on digital stereoscopic fundus photography from baseline (ie, prior to ABBV-RGX-314 administration in the parent study)
Tidsram: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in BCVA
Tidsram: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Proportion of participants gaining or losing ≥ 5, 10, and 15 letters in BCVA compared with baseline (ie, prior to ABBV-RGX-314 administration in the parent study)
Tidsram: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in CST as measured by SD-OCT
Tidsram: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in the area of retinal nonperfusion on ultra-widefield Optos FA
Tidsram: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean number of anti-VEGF injections through years 2, 3, 4, and 5 based on ongoing chart review in the study eye (DL4 participants only)
Tidsram: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean number of anti-VEGF injections in years 2, 3, 4, and 5 based on ongoing chart review in the study eye (DL4 participants only)
Tidsram: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean anti-VEGF injection annualized rate through years 2, 3, 4, and 5 based on ongoing chart review in the study eye (DL4 participants only)
Tidsram: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean anti-VEGF injection annualized rate in years 2, 3, 4, and 5 based on ongoing chart review in the study eye (DL4 participants only)
Tidsram: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean number of retina specialist visits attended for complications of DR based on chart review
Tidsram: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Sjukdomar i det endokrina systemet
- Kärlsjukdomar
- Hjärt-kärlsjukdomar
- Diabetes mellitus
- Ögonsjukdomar
- Diabetiska angiopatier
- Diabeteskomplikationer
- Näthinnesjukdomar
- Diabetisk retinopati
- Administration
- Sjukvårdskvalitet, tillgång och utvärdering
- Hälsovårdskvalitet
- Kvalitetsindikatorer, hälsovård
- Vårdstandard
- förflyttning
Andra studie-ID-nummer
- RGX-314-5201 (M23-420)
- M23-420 (Annan identifierare: AbbVie Inc)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Tidsram för IPD-delning
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
Kriterier för IPD Sharing Access
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .